Edwards Lifesciences Announces Long-Term Benefits of Sapien Heart Valve System
Edwards Lifesciences (NYSE: EW) announced new data demonstrating long-term benefits with its Sapien heart valve system.
Seven-year data from the PARTNER 3 trial showed sustained patient benefits of Edwards’ transcatheter aortic valve replacement (TAVR) system, with superior clinical outcomes at one year and strong long-term valve performance and durability.
Additionally, 10-year results from PARTNER 2 intermediate risk studies reinforced the company’s valve’s lasting performance and outcomes across all risk profiles and generations.
These findings were shared at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, along with new long-term findings for the Evoque and Sapien M3 valves.
Edwards Lifesciences (NYSE: EW) + announced new data demonstrating long-term benefits with its Sapien heart valve system.
Author summary: Edwards Lifesciences shares long-term benefits of Sapien heart valve system.
More News
- Flyers send Jett Luchanko back to juniors as development takes priority | NorthPennNow
- Bitcoin Price Might Never Fall Below $100,000 Again
- Canadian Immigration Didn’t Tank (Or Help) The Economy: CIBC - Better Dwelling
- UAMS receives $4 million to reduce maternal mortality in Ashley and Union counties - Talk Business & Politics
- Michael Clark murder defense seeks to link case to JonBenét investigation
- “No Faux King Way”: ‘No Kings’ Protesters Fighting Against Trumpism And White Christian Nationalists - Black Star News
- SJHN Daily: Celebrini Named NHL First Star of the Week